5-氨基酮戊酸光动力筛选用于胰腺癌诊断的有效性。
Effectiveness of Photodynamic Screening Using 5-Aminolevulinic Acid for the Diagnosis of Pancreatic Cancer.
机构信息
The Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan
The Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
出版信息
Anticancer Res. 2020 Jun;40(6):3571-3577. doi: 10.21873/anticanres.14347.
BACKGROUND/AIM: We evaluated urinary levels of porphyrin metabolites, such as uroporphyrin (UP) and coproporphyrin (CP), after 5-Aminolevulinic acid (ALA) administration in patients with or without pancreatic cancer (PaC).
PATIENTS AND METHODS
Sixty-seven subjects with PaC, 11 with pancreatitis, and 9 with normal pancreas (NP) were enrolled. Urine samples from all subjects were collected prior to ALA administration and at more than 4 hours after ALA administration. We measured the urinary levels of UP and CP by high-performance liquid chromatography analysis.
RESULTS
The PaC group showed significantly higher UP levels compared to NP groups (104.9 nmol/g Cre vs. 53.4 nmol/g Cre, p=0.014). Moreover, PaC patients with long-term survival had significantly lower urinary levels of UP at diagnosis (98.8 nmol/gCre) than the short-term survival group (125.2 nmol/gCre) (p=0.042).
CONCLUSION
The urinary levels of UP after ALA administration might serve as a promising biomarker for diagnosis and prognosis prediction of PaC.
背景/目的：我们评估了 5-氨基酮戊酸（ALA）给药后有无胰腺癌（PaC）患者尿液中卟啉代谢物（如尿卟啉（UP）和粪卟啉（CP））的水平。
患者和方法
共纳入 67 例 PaC 患者、11 例胰腺炎患者和 9 例正常胰腺（NP）患者。所有患者在 ALA 给药前和 ALA 给药后 4 小时以上采集尿液样本。我们通过高效液相色谱分析测定 UP 和 CP 的尿水平。
结果
与 NP 组相比，PaC 组的 UP 水平明显更高（104.9 nmol/g Cre 比 53.4 nmol/g Cre，p=0.014）。此外，长期生存的 PaC 患者在诊断时的 UP 尿水平明显低于短期生存组（98.8 nmol/gCre 比 125.2 nmol/gCre，p=0.042）。
结论
ALA 给药后 UP 的尿水平可能成为 PaC 诊断和预后预测的有前途的生物标志物。
Zotero 插件